GSK Pharma put volume heavy and directionally bearish
Pharma with 2,330 puts trading, or 1.1x expected. Most active are 2/14 weekly 36 puts and 2/28 weekly 36 puts, ...
Hedge Fund Citadel takes short position in GSK, FT reports
Hedge fund Citadel has made a 305 million pound ($384.5 million) bet against drugmaker GSK , the Financial Times reported on ...
GSK shares shorted by leading U.S. hedge fund, The Times reports
The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s ...
The Boston Globe4d
GSK to grow Massachusetts work force with move from Maryland
Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...
Seeking Alpha9d
GSK outlines 2025 growth driven by specialty medicines and new product launches
CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...
Insider Monkey8d
Why GSK plc (GSK) Went Up on Wednesday
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...
The Financial Times9d
GSK is emerging from its long convalescence
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK does not need a miracle cure — just some rest and rehabilitation. Investors, though, seem unwilling ...
Insider Monkey9d
Why GSK Stock Is Surging Today
GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...
Reuters10d
GSK, gold miners shares push Britain's FTSE 100 higher
Feb 5 (Reuters) - UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold miners, while investors turned their focus to the Bank ...
The Motley Fool UK7d
Down 15% and with a P/E below 9! Is the GSK share price still in deep value territory?
Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...
pharmaphorum3d
GSK says $2.2bn settlement resolves most Zantac litigation
GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...
The Motley Fool UK23d
Anywhere under £45.27, GSK’s share price looks cheap to me
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...